



(43) International Publication Date
25 June 2015 (25.06.2015)

(10) International Publication Number
WO 2015/092740 A1

(51) International Patent Classification:

C07D 231/12 (2006.01) *C07D 413/12* (2006.01)
A61K 31/41 (2006.01) *C07D 417/12* (2006.01)
A61K 31/415 (2006.01) *C07D 257/04* (2006.01)
A61K 31/42 (2006.01) *C07D 271/10* (2006.01)
C07D 401/12 (2006.01)

(21) International Application Number:

PCT/IB2014/067086

(22) International Filing Date:

18 December 2014 (18.12.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13199138.2 20 December 2013 (20.12.2013) EP
14181155.4 15 August 2014 (15.08.2014) EP

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(71) Applicants (for US only): **BOLLBUCK, Birgit** [DE/CH]; Novartis Pharma AG, Novartis Institutes for Biomed. Research, Postfach, CH-4002 Basel (CH). **MARKERT, Christian** [DE/CH]; Novartis Pharma AG, Novartis Institutes for Biomed. Research, Postfach, CH-4002 Basel (CH). **MILTZ, Wolfgang** [DE/CH]; Novartis Pharma AG, Novartis Institutes for Biomed. Research, Postfach, CH-4002 Basel (CH). **ROEHN, Till** [DE/CH]; Novartis Pharma AG, Novartis Institutes for Biomed. Research, Postfach, CH-4002 Basel (CH).

(74) Common Representative: **NOVARTIS AG**; Lichtstrasse 35, CH-4056 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: HETEROARYL BUTANOIC ACID DERIVATIVES AS LTA4H INHIBITORS

(57) Abstract: The present invention describes novel heteroaryl butanoic acid derivatives that are good drug candidates especially with regard to leukotriene A4 hydrolase (LTA4H). The present invention also relates to pharmaceutical compositions comprising said novel heteroaryl butanoic acid derivatives, methods of using said compounds in the treatment of various diseases and disorders, and processes for preparing the said novel compounds.



WO 2015/092740 A1